Other Events ·
Galmed Pharmaceuticals Ltd. announced the development of a novel lipid nanoparticle (LNP) formulation of its SCD1…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. announced the development of a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, which targets the heart tissue to treat cardiac fibrosis. This breakthrough development was achieved through a collaboration with Barcode Nanotech using an AI-enabled screening platform to improve biodistribution. Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and GI oncology diseases.